US Pat. No. 10,765,673

METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES

Eutropics Pharmaceuticals...

1. A method of inhibiting MCL-1 in a cell, comprising contacting the cell with an effective amount of a compound selected from:7-((4-methoxyphenyl)(morpholino)methyl)quinolin-8-ol (1);
7-((2,6-dimethylmorpholino)(pyridin-2-yl)methyl)quinolin-8-ol (2);
7-(morpholino(pyridin-2-yl)methyl)quinolin-8-ol (3);
7-(morpholino(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (5);
7-((4-chlorophenyl)(piperidin-1-yl)methyl)quinolin-8-ol (6);
7-((4-fluorophenyl)(morpholino)methyl)quinolin-8-ol (7);
ethyl 4-((8-hydroxyquinolin-7-yl)(pyridin-2-yl)methyl)piperazine-1-carboxylate (10),
7-((4-(2-hydroxyethyl)piperazin-1-yl)(phenyl)methyl)quinolin-8-ol (13); and
tert-butyl 4-((4-fluorophenyl)(8-hydroxyquinolin-7-yl)methyl)piperazine-1-carboxylate (14).
US Pat. No. 10,766,953

ANTI-PHF-TAU ANTIBODIES AND USES THEREOF

Janssen Biotech, Inc., H...

1. An isolated antibody or antigen binding fragment thereof which binds to PHF tau comprising:a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7,
b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8,
c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9,
d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:19,
e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:20, and
f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:21.
US Pat. No. 10,767,209

DEVICE AND METHOD FOR DETECTING PLANT PATHOGENS

FUNGIALERT LIMITED, Harp...

1. A method for in-situ detection of microorganisms or plant pathogens directly at a site of soil or water employing a detection device comprising:placing a support member of the detection device in contact with the soil or water, wherein the support member contains a plant pathogen chemoattractant absorbed by the support member to attract the microorganisms or the plant pathogens in the soil or water into the detection device, wherein the support member is the only part of the device inserted into the soil or water and insertion is located in the soil or water at a location of plant growth or a location being considered for plant growth; and
detecting the microorganisms or the plant pathogens directly at the site of the soil or water after placing the support member of the detection device in contact with the soil or water;
wherein the support member comprises material that allows the microorganisms or the plant pathogens to flow within the detection device from one end of the support member to another end of the support device via a filter positioned within the detection device that selectively allows only the microorganisms or the plant pathogens to be detected to reach a culture medium also within a container and connected to the filter; and
wherein the culture medium contains a plant pathogen chemoattractant which attracts the microorganisms or the plant pathogens, and the culture medium further contains a detection means capable of detecting the microorganisms or the plant pathogens.
US Pat. No. 10,765,674

PREVENTION OF HIV-INFECTION

Janssen Sciences Ireland ...

1. A method of maintaining a blood plasma level of 4-1000 ng/ml of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]-amino]benzonitrile, the E isomeric form thereof or the Z-isomeric form thereof in an individual at risk of being infected with HIV-1, comprisingsubcutaneously or intramuscularly injecting a solution into the individual, intermittently at a time interval of at least one week, wherein said solution comprises:
sterile water;
a solubilizer or a surfactant; and
a dose, calculated on a basis of 0.2 mg/day to 50 mg/day of the time interval, of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]-amino]benzonitrile, the E isomeric form thereof or the Z-isomeric form thereof; or a pharmaceutically acceptable acid-addition salt thereof;
wherein the blood plasma level is maintained over the time interval.
US Pat. No. 10,766,954

THERAPEUTIC ANTIBODIES FOR TREATMENT OF NEURODEGENERATION

Imago Pharmaceuticals, In...

1. A therapeutic monoclonal antibody comprising the VL CDRs of SEQ ID NO:1, SEQ NO:2 and SEQ NO: 3 and comprising the VH CDRs of SEQ ID NO:4, SEQ NO:5 and SEQ NO: 6.
US Pat. No. 10,765,675

COMPOSITIONS AND METHODS FOR TREATING EWING FAMILY TUMORS

The Methodist Hospital, ...

1. A method for treating a sarcoma, the method comprising administering to a subject having a sarcoma an effective amount of imatinib and metformin.
US Pat. No. 10,766,955

ANTI-TGF-? ANTIBODIES AND THEIR USE

SANOFI, Paris (FR)

1. A method of inhibiting TGF-? signal transduction in a patient in need thereof, comprising administering to the patient a therapeutic amount of an isolated monoclonal antibody, wherein the antibody binds to human TGF-?1, TGF-?2, and TGF-?3 and comprises the heavy chain complementarity-determining regions (CDR) 1-3 in SEQ ID NO:1 and the light chain CDR1-3 in SEQ ID NO:2, and wherein the antibody comprises a human IgG4 constant region having a proline at position 228 (EU numbering).
US Pat. No. 10,767,211

MODIFIED AMADORIASE REACTING WITH FRUCTOSYL HEXAPEPTIDE

Kikkoman Corporation, Ch...

1. A variant amadoriase comprising an amino acid sequence which exhibits 90% or higher sequence identity with the amino acid sequence as shown in SEQ ID NO: 1 over the full length in which, when said amino acid sequence is aligned with the amino acid sequence as shown in SEQ ID NO: 1, the amino acid at the position corresponding to position 62 of the amino acid sequence as shown in SEQ ID NO: 1 is alanine or aspartic acid and having activity on ?-fructosyl hexapeptide (?F6P) greater than the activity of an amadoriase having the amino acid sequence as shown in SEQ ID NO: 1.
US Pat. No. 10,766,956

ANTAGONIST ANTIBODIES THAT BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS

UCB BIOPHARMA SRL, Bruss...

1. An antagonistic antibody, or a binding fragment thereof, which binds human TGF-beta 1, human TGF-beta 2 and human TGF-beta 3 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises a CDR having the sequence given in SEQ ID NO:4 for CDR-H1, a CDR having the sequence given in SEQ ID NO:5 for CDR-H2 and a CDR having the sequence given in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9 for CDR-H3, and wherein the variable domain of the light chain comprises a CDR having the sequence given in SEQ ID NO:1 for CDR-L1, a CDR having the sequence given in SEQ ID NO:2 for CDR-L2 and a CDR having the sequence given in SEQ ID NO:3 for CDR-L3.
US Pat. No. 10,767,212

METHOD OF SCREENING COMPOUNDS

Cornell University, Itha...

1. A method of screening for compounds that bind to the activation loop of kidney-type glutaminase (“GLS”) protein, said method comprising:contacting GLS protein, wherein the GLS protein comprises an activation loop and comprises a phenylalanine to tryptophan substitution at the residue corresponding to position 322 of SEQ ID NO: 2, with a test compound, wherein the test compound is a compound that potentially binds to the activation loop, to permit binding between the activation loop and the test compound;
detecting fluorescence of the substituted tryptophan in the presence of the test compound;
comparing the detected fluorescence to fluorescence of a control; and
identifying, based on said comparing, that the test compound is a compound that binds to the activation loop of GLS, wherein a change in fluorescence relative to the control indicates that the test compound binds to the activation loop.
US Pat. No. 10,765,677

STABLE AND SOLUBLE FORMULATIONS OF RECEPTOR TYROSINE KINASE INHIBITORS, AND METHODS OF PREPARATION THEREOF

ForSight Vision4, Inc., ...

1. A method of treating an ophthalmic disease or disorder in a subject in need thereof, the method comprising administering to an eye of the subject an effective amount of a pharmaceutical solution comprising:(i) ?-cyclodextrin sulfobutyl ether, hydroxypropyl ?-cyclodextrin, or a combination thereof;
(ii) about 0.2% to about 1.0% of polyvinylpyrrolidone; and
(iii) about 30 mg/mL to about 60 mg/mL of an ophthalmic therapeutic agent or a pharmaceutically acceptable salt thereof having a solubility of less than 1 mg/mL in water.
US Pat. No. 10,766,957

ANTI-TIGIT ANTIBODIES

1. An antibody or antigen binding fragment thereof that binds to human T cell immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain variable region CDR1, a heavy chain variable region CDR2, and a heavy chain variable region CDR3, and the light chain variable region comprises a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3; and wherein the antibody or antigen binding fragment thereof is selected from the group consisting of:a. an antibody or antigen binding fragment thereof comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, 45, 46, or 47, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6, 57, 58, 59, 60, 61, or 62; and
b. an antibody or antigen binding fragment thereof comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:17, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:18, 81, 82, 83, 84, 85, 86, 87, or 88, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:19, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:20, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:21, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22.
US Pat. No. 10,765,678

POLYMORPHS OF ARRY-380, A SELECTIVE HER2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Array BioPharma Inc., Bo...

1. A method of treating cancer in a mammal in need thereof comprising administering a therapeutically effective amount of a crystalline polymorph of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine to the mammal, wherein the polymorph is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form O and Form P, and wherein the cancer is ErbB2 positive colorectal, gastric or esophageal cancer.
US Pat. No. 10,766,958

METHODS OF TREATING VITILIGO USING PD-1 BINDING ANTIBODIES

Celgene Corporation, Sum...

1. A method of managing or treating vitiligo in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to PD-1, wherein the antibody or antigen-binding fragment comprises:a light chain variable region (VL) comprising:
a VL complementarity determining region 1 (CDR1) comprising SEQ ID NO:1,
a VL CDR2 comprising SEQ ID NO:2, and
a VL CDR3 comprising SEQ ID NO:3; and
a heavy chain variable region (VH) comprising:
a VH CDR1 comprising SEQ ID NO:4,
a VH CDR2 comprising SEQ ID NO:5, and
a VH CDR3 comprising SEQ ID NO:6.
US Pat. No. 10,767,214

METHOD OF MICROVESICLE ENRICHMENT

CLINICAL GENOMICS PTY LTD...

1. A method of enriching for membranous microvesicles from a mammalian biological sample, the method comprising(a) subjecting the biological sample to a single step membranous microvesicle enrichment, wherein the single step consists of mechanical cellular rupture selected from the group consisting of
(i) centrifugation;
(ii) sonication, with or without the inclusion of surfactants;
(iii) bead milling with or without the addition of surfactants using small glass;
ceramic, zirconium or steel beads;
(iv) homogenization;
(v) using a nitrogen burst method;
(vi) using a small probe ultrasound;
(vii) using hypotonic shock;
(viii) using high-shear mechanical methods;
(ix) using rotor-stator disruptors;
(x) using valve-type processors;
(xi) using fixed geometry processors;
(xii) using constant pressure processors;
(xiii) using osmosis based electroporation; and
(xiv) electropermeabilization,
and wherein the mechanical cellular rupture selectively ruptures residual cells but not membranous microvesicles, and
(b) lysing the enriched membranous microvesicles resulting from the single step in (a) to release their nucleic acid and protein content.
US Pat. No. 10,765,679

USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION

Emory University, Atlant...

1. A method for treating an HIV infection, comprising administering to a patient in need thereof an effective antiviral amount of a TREM-1 inhibitor in combination with HAART.
US Pat. No. 10,766,959

ANTI-C10ORF54 ANTIBODIES AND USES THEREOF

Pierre Fabre Medicament, ...

1. An isolated antibody or antigen-binding fragment thereof that binds to a C10orf54 protein, comprising:a heavy chain comprising the following three CDRs, respectively CDR-H1 having the sequence SEQ ID NO: 1296, CDR-H2 having a sequence selected from SEQ ID NO: 1358, SEQ ID NO. 1556, SEQ ID NO. 1557, SEQ ID NO. 1558, and SEQ ID NO. 1559, and CDR-H3 having the sequence SEQ ID No. 1393; and
a light chain comprising the following three CDRs, respectively CDR-L1 having the sequence SEQ ID No. 1435, CDR-L2 having a sequence selected from SEQ ID NO: 1476, SEQ ID NO. 1630, SEQ ID NO. 1631, SEQ ID NO. 1632, and SEQ ID NO. 1633, and CDR-L3 having the sequence SEQ ID No. 1499.
US Pat. No. 10,767,215

STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID

DNA GENOTEK INC., Ottawa...

1. A phenol-free method for preserving ribonucleic acid from a biological sample comprising the steps of:a. obtaining the sample from a subject;
b. contacting the sample with a composition comprising an anionic detergent, wherein the anionic detergent is at a concentration of 1% to 8%, and a buffering agent at a pH of about 5 to about 8.2 to form a mixture; and
c. storing the mixture at room temperature;wherein the composition stabilizes the ribonucleic acid at room temperature.
US Pat. No. 10,765,680

COMBINATION OF A MCL-1 INHIBITOR AND A TAXANE COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF

LES LABORATORIES SERVIER,...

1. A combination comprising:(a) an MCL-1 inhibitor which is (2R)-2-{[(5Sa)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(5-fluorofuran-2-yl)thieno{2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]methoxy}phenyl)propanoic acid or (2R)-2-{[5Sa)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno [2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid
or an addition salt thereof with a pharmaceutically acceptable acid or base,
and (b) a taxane compound which is paclitaxel or docetaxel.
US Pat. No. 10,766,960

HETERODIMERIZED POLYPEPTIDE

Chugai Seiyaku Kabushiki ...

1. A heterodimer comprising a first polypeptide and a second polypeptide,wherein the first polypeptide comprises an IgG Fc region comprising a set of amino acids selected from the group consisting of sets (a) to (aj) below (all positions by EU numbering):
(a) amino acid E at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; amino acid D at position 327;
(b) amino acid S at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(c) amino acid L at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(d) amino acid L at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(e) amino acid S at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(f) amino acid F at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(g) amino acid E at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(h) amino acid F at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(i) amino acid V at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(j) amino acid D at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(k) amino acid Q at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(l) amino acid I at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(m) amino acid M at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(n) amino acid T at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(o) amino acid A at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(p) amino acid G at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(q) amino acid H at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(r) amino acid V at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(s) amino acid D at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(t) amino acid Q at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(u) amino acid I at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(v) amino acid M at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(w) amino acid T at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(x) amino acid A at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(y) amino acid G at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(z) amino acid H at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid M at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(aa) amino acid F at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(ab) amino acid E at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(ac) amino acid D at position 234; amino acid Q at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid E at position 270; and amino acid A at position 298;
(ad) amino acid V at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(ae) amino acid I at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(af) amino acid L at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(ag) amino acid E at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(ah) amino acid D at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327;
(ai) amino acid F at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327; and
(aj) amino acid T at position 234; amino acid Y at position 235; amino acid W at position 236; amino acid I at position 239; amino acid D at position 268; amino acid A at position 298; and amino acid D at position 327; and
the second polypeptide comprises an IgG Fc region that is different from the Fc region of the first polypeptide and comprises a set of amino acids selected from the group consisting of sets (ak) to (aq) (all positions by EU numbering):
(ak) amino acid E at position 270; amino acid D at position 326; amino acid K at position 330; and amino acid E at position 334;
(al) amino acid E at position 270; amino acid D at position 326; amino acid M at position 330; and amino acid E at position 334;
(am) amino acid E at position 270; amino acid D at position 326; amino acid A at position 330; and amino acid E at position 334;
(an) amino acid E at position 270; amino acid D at position 326; amino acid F at position 330; and amino acid E at position 334;
(ao) amino acid E at position 270; amino acid D at position 326; amino acid I at position 330; and amino acid E at position 334;
(ap) amino acid E at position 270; amino acid D at position 326; amino acid Y at position 330; and amino acid E at position 334; and
(aq) amino acid E at position 270; amino acid D at position 326; amino acid H at position 330; and amino acid E at position 334.
US Pat. No. 10,766,961

ANTI-VEGFR2 ANTIBODY THERAPY FOR HEPATOCELLULAR CARCINOMA

ImClone LLC, Indianapoli...

1. A method of selecting a patient having a hepatocellular tumor and treating said patient with a therapeutically effective amount of ramucirumab, comprising assaying for the level of alpha-fetoprotein in a plasma or serum sample taken from the patient, and selecting and treating the patient with a therapeutically effective amount of ramucirumab if the level of alpha-fetoprotein in the sample is 400 ng/mL or greater.
US Pat. No. 10,767,217

COMPOSITIONS, METHODS AND KITS FOR REAL TIME POLYMERASE CHAIN REACTION (PCR)

Life Technologies Corpora...

1. A method for amplifying a target nucleic acid comprising:a) contacting the target nucleic acid with a first nucleic acid polymerase, a dual hot start reaction mixture, at least one primer and at least one dNTP at a first temperature, thereby forming a reaction composition, wherein the dual hot start reaction mixture comprises at least two hot start mechanisms that, together, both inhibit activity of the first nucleic acid polymerase;
b) heating the reaction composition to a second temperature; and
c) amplifying the target nucleic acid in the reaction composition.